Anlong Bio
Beijing
About Anlong Bio
Anlong Bio focuses on the research and development of nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. The core team has experience in domestic and foreign scientific research, multinational pharmaceutical companies, entrepreneurship, and investment. In the fields with huge market potential, the varieties of independent intellectual property rights are developed, and most of them are at the forefront of the country. In the field of rare diseases, they use the rich resources of rare disease patients in China to actively cooperate with foreign companies. The company aims to provide various genetic medicines to fulfill the unmet medical need in China, they develop AAV gene therapies with in-house technologies from vector discoveries to manufacturing and clinical approval.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $14.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: anlongbio.com
- Phone: 86-10-80414166
Industries & Categories
Genetics, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/anlong-bio-57486 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.